Hidradenitis suppurativa (HS) is a chronic, painful skin condition characterized by inflamed nodules, abscesses, and scarring, primarily in areas with sweat glands. According to Kimberly Ballard et al., 2024, the disease accounts for around 1% to 4% of the global population. The drug pipeline for HS includes promising biologics such as Bimekizumab, targeting key inflammatory pathways. According to the hidradenitis suppurativa pipeline analysis by Expert Market Research, there is a growing focus on developing novel immunomodulatory therapies and precision medicine for the condition. Rising awareness, improved diagnosis, and ongoing clinical trials are expected to drive significant market growth in the coming years.
Major companies involved in the hidradenitis suppurativa pipeline analysis include Avalo Therapeutics, Inc., Citryll BV, and others.
Leading drugs currently in the pipeline include AVTX-009, CIT-013, SBT777101, and others.
The hidradenitis suppurativa drug pipeline is expanding due to increasing R&D in biologics, rising clinical trials for IL-17 inhibitors, and growing FDA designations for novel therapies.
The Hidradenitis Suppurativa Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hidradenitis suppurativa therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hidradenitis suppurativa. The hidradenitis suppurativa report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hidradenitis suppurativa pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hidradenitis suppurativa treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hidradenitis suppurativa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition characterized by painful, boil-like lumps, typically forming in areas where skin rubs together, such as the armpits, groin, and under the breasts. It occurs due to follicular occlusion, inflammation, and immune system dysregulation, often resulting in abscesses, tunnels under the skin, and scarring over time.
Hidradenitis suppurativa is treated through antibiotics, corticosteroids, hormonal therapy, immunosuppressants, and biologics to reduce inflammation, manage symptoms, and prevent flare-ups, with treatment tailored to disease severity and progression. In October 2023, the United States Food and Drug Administration approved Novartis’ Cosentyx® (secukinumab) as the first IL-17A inhibitor for moderate to severe hidradenitis suppurativa, demonstrating early and sustained symptom relief in pivotal Phase III trials.
According to Kimberly Ballard et al., 2024, the estimated prevalence of hidradenitis suppurativa ranges from 1%-4%, with figures likely underestimated due to underreporting and misdiagnosis. As per Verma, Kritin K et al., 2024, a large-scale study involving 407,333 individuals reported a prevalence of 0.40%, with a female-to-male ratio of 4:1. The highest prevalence was observed in individuals aged 18–25 years and among Black patients at 0.76%.
This section of the report covers the analysis of hidradenitis suppurativa drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II (at 37%), covers a major share of the total hidradenitis suppurativa clinical trials. It is followed closely by phase III with 37%. Phase I accounts for 16%. The strong presence in advanced stages reflects growing research interest, which is expected to positively impact the hidradenitis suppurativa treatment landscape through improved treatment outcomes and drug availability.
The drug molecule categories covered under the hidradenitis suppurativa pipeline analysis include small molecules, gene therapies, monoclonal antibodies, peptides, and polymers. The hidradenitis suppurativa report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hidradenitis suppurativa. Interleukin inhibitors are emerging as a promising drug class in the hidradenitis suppurativa treatment pipeline. For instance, lutikizumab, a dual-variable-domain interleukin-1α/1β antagonist, demonstrated higher HiSCR 50 response rates in a Phase 2 trial. It is now advancing to Phase 3, targeting inflammatory pathways linked to moderate to severe hidradenitis suppurativa in patients unresponsive to anti-TNF therapies.
The EMR report for the hidradenitis suppurativa pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a hidradenitis suppurativa therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hidradenitis suppurativa clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hidradenitis suppurativa. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hidradenitis suppurativa drug candidates.
AVTX-009 is a humanized monoclonal antibody targeting interleukin-1 beta, that neutralizes the inflammatory activity in moderate to severe hidradenitis suppurativa. Sponsored by Avalo Therapeutics, Inc., the Phase 2 LOTUS study is evaluating the drug’s efficacy and safety compared to placebo. Researchers are assessing how AVTX-009 is reducing HS symptoms over a 16-week treatment period, with patients receiving one of two dosage regimens or placebo.
CIT-013, sponsored by Citryll BV, is currently being evaluated in a Phase 2a trial for hidradenitis suppurativa (HS). This study aims to determine whether CIT-013 can reduce the disease activity and assess its safety profile. CIT-013 is a first-in-class monoclonal antibody designed to prevent and clear extracellular traps, such as NETs and EETs, which are linked to chronic inflammation in HS and other immune-mediated disorders.
SBT777101, sponsored by Sonoma Biotherapeutics, Inc., is currently undergoing a Phase 1 clinical trial to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with hidradenitis suppurativa. This study is examining the effects of single ascending doses of SBT777101, an autologous CAR-Treg cell therapy designed to target inflamed tissue. The objective is to reduce inflammation and restore immune balance using next-generation genome-edited regulatory T cells.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hidradenitis Suppurativa Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hidradenitis suppurativa. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hidradenitis suppurativa collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share